AllianceRx Walgreens Prime Continues as Exclusive Pharmacy for Cystaran
Cystaran is a topical ophthalmic therapy that is used to treat a rare genetic disorder.
Leadiant Biosciences has chosen AllianceRx Walgreens Prime to be the exclusive specialty pharmacy and clinical support provider as it relaunches its rare disease drug Cystaran (cysteamine) ophthalmic solution. Cystaran is used to treat corneal cystine crystals in patients with cystinosis, a rare, multi-system genetic disorder that typically manifests in early childhood.
The two companies have partnered since 2014, and Leadiant recently relaunched Cystaran with revised packaging.
Tracey James, RPh
“Our organizations are aligned in wanting the best possible outcomes for the patients,” Tracey James, RPh, Senior Vice President, Pharmacy Services, at AllianceRx Walgreens Prime, said in a press release.
Cystinosis causes an abnormal accumulation of the amino acid cystine in various organs and tissues of the body including the eyes, kidneys, muscles, pancreas, and brain. The cystine accumulation causes widespread tissue and organ damage.
Cystinosis affects about 1 in 100,000 to 200,000 newborns worldwide, according to the National Institutes of Health. It is caused by mutations in the CTNS gene.
AllianceRx Walgreens Prime is a specialty and home delivery pharmacy. In January, URAC issued a reaccreditation for the specialty pharmacy services offered by AllianceRx Walgreens Prime.
Its customized Connected Care Cystaran program provides patient support and clinical interventions specific to each patient's self-reported issues. Through the program, pharmacists regularly connect with patients to address any issues they have.
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More
